The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy.

Details

Ressource 1Download: The Anticancer Drug Tamoxifen Counteracts the Pathology in a Mouse Model of Duchenne Muscular Dystrophy.pdf (1519.51 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_FDDDD54C235C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy.
Journal
The American journal of pathology
Author(s)
Dorchies O.M., Reutenauer-Patte J., Dahmane E., Ismail H.M., Petermann O., Patthey- Vuadens O., Comyn S.A., Gayi E., Piacenza T., Handa R.J., Décosterd L.A., Ruegg U.T.
ISSN
1525-2191 (Electronic)
ISSN-L
0002-9440
Publication state
Published
Issued date
02/2013
Peer-reviewed
Oui
Volume
182
Number
2
Pages
485-504
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Duchenne muscular dystrophy (DMD) is a severe disorder characterized by progressive muscle wasting,respiratory and cardiac impairments, and premature death. No treatment exists so far, and the identification of active substances to fight DMD is urgently needed. We found that tamoxifen, a drug used to treat estrogen-dependent breast cancer, caused remarkable improvements of muscle force and of diaphragm and cardiac structure in the mdx(5Cv) mouse model of DMD. Oral tamoxifen treatment from 3 weeks of age for 15 months at a dose of 10 mg/kg/day stabilized myofiber membranes, normalized whole body force, and increased force production and resistance to repeated contractions of the triceps muscle above normal values. Tamoxifen improved the structure of leg muscles and diminished cardiac fibrosis by~ 50%. Tamoxifen also reduced fibrosis in the diaphragm, while increasing its thickness,myofiber count, and myofiber diameter, thereby augmenting by 72% the amount of contractile tissue available for respiratory function. Tamoxifen conferred a markedly slower phenotype to the muscles.Tamoxifen and its metabolites were present in nanomolar concentrations in plasma and muscles,suggesting signaling through high-affinity targets. Interestingly, the estrogen receptors ERa and ERb were several times more abundant in dystrophic than in normal muscles, and tamoxifen normalized the relative abundance of ERb isoforms. Our findings suggest that tamoxifen might be a useful therapy for DMD.
Keywords
Animals, Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Behavior, Animal/drug effects, Biomarkers/metabolism, Biomechanical Phenomena/drug effects, Body Weight/drug effects, Creatine Kinase/blood, Diaphragm/pathology, Diaphragm/physiopathology, Disease Models, Animal, Feeding Behavior/drug effects, Fibrosis, Mice, Muscle Contraction/drug effects, Muscle Fibers, Skeletal/drug effects, Muscle Fibers, Skeletal/pathology, Muscular Dystrophy, Animal/blood, Muscular Dystrophy, Animal/drug therapy, Muscular Dystrophy, Animal/pathology, Muscular Dystrophy, Animal/physiopathology, Muscular Dystrophy, Duchenne/blood, Muscular Dystrophy, Duchenne/drug therapy, Muscular Dystrophy, Duchenne/pathology, Muscular Dystrophy, Duchenne/physiopathology, Myocardium/pathology, Organ Size/drug effects, Receptors, Estrogen/metabolism, Tamoxifen/blood, Tamoxifen/pharmacology, Tamoxifen/therapeutic use
Pubmed
Web of science
Open Access
Yes
Create date
07/03/2013 19:21
Last modification date
09/07/2024 7:19
Usage data